Novo Nordisk’s IP Group looks beyond the financial ROI to Real Efficiency and Engagement
Novo Nordisk is a global pharmaceutical company with 90 years of innovation and leadership in diabetes care. Their intellectual property (IP) team consists of 65 people with a wide geographic spread between their corporate headquarters in Denmark and additional IP units in the United States, India, and China.
Find out here how the implementation of the new 'Enterprise Platform' led to a 120% increase in daily use by staff and a 40% cost savings.
Please note: That all fields marked with an asterisk (*) are required.